The ability of bacteria to activate the terminal complement components in serum of patients with cystic fibrosis.

[1]  L. Guthrie,et al.  Alternative complement pathway activity in cystic fibrosis. , 1977, The Journal of pediatrics.

[2]  A. Goldman.  Birth defects and drugs in pregnancy , 1977 .

[3]  M. Polley,et al.  Cystic fibrosis: current concepts. , 1974, Journal of medical genetics.

[4]  W. Wood,et al.  Heat Labile Opsonins to Pneumococcus , 1972, The Journal of Immunology.

[5]  W. Wood,et al.  Heat labile opsonins to pneumococcus. II. Involvement of C3 and C5. , 1969 .